Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$141.57
+3.6%
$129.05
$116.23
$158.45
$8.14B1.03431,122 shs516,384 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$33.53
+3.9%
$30.59
$23.95
$52.34
$5.34B0.151.56 million shs1.44 million shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$79.52
-2.7%
$99.15
$75.00
$126.89
$5.45B0.23969,857 shs2.17 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
+3.58%+7.43%+10.64%+9.68%+19.63%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
+3.94%-0.36%+20.18%+6.17%-14.20%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-2.86%-26.36%-22.04%-2.93%+4.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
4.708 of 5 stars
2.44.03.34.83.12.51.3
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4.4952 of 5 stars
4.31.00.03.04.13.30.6
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.4273 of 5 stars
3.51.00.04.23.12.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
2.83
Moderate Buy$163.5015.49% Upside
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.65
Moderate Buy$56.6769.00% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$132.6766.83% Upside

Current Analyst Ratings Breakdown

Latest ENSG, LNTH, and IONS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $117.00
5/2/2025
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$159.00 ➝ $156.00
5/1/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$65.00 ➝ $64.00
5/1/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $50.00
4/30/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $55.00
4/15/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
4/8/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
4/7/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$45.00
4/7/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$45.00
4/3/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/31/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$39.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$4.42B1.84$7.31 per share19.37$32.03 per share4.42
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$717.25M7.44N/AN/A$3.70 per share9.06
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.54B3.54$6.64 per share11.98$11.91 per share6.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$297.97M$5.2927.7022.941.526.99%17.07%6.47%7/24/2025 (Estimated)
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$366.29M-$2.99N/AN/AN/A-64.25%-100.05%-15.70%N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$326.66M$3.5213.2312.60N/A28.57%44.29%23.52%7/30/2025 (Estimated)

Latest ENSG, LNTH, and IONS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
4/30/2025Q1 2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million
4/29/2025Q1 2025
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$1.50$1.52+$0.02$1.37$1.17 billion$1.17 billion
2/27/2025Q4 2024
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million
2/19/2025Q4 2024
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$1.12-$0.66+$0.46-$0.66$140.97 million$227.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$0.250.18%+4.50%4.73%18 Years
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A

Latest ENSG, LNTH, and IONS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/20/2025
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
quarterly$0.06250.2%3/31/20253/31/20254/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
0.08
1.56
1.56
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.12
8.47
8.82
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/A
1.65
1.56

Institutional Ownership

CompanyInstitutional Ownership
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
96.12%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
93.86%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%

Insider Ownership

CompanyInsider Ownership
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
3.90%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.60%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
29,90057.49 million55.21 millionOptionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
800159.16 million153.62 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70068.48 million68.48 millionOptionable

Recent News About These Companies

Shine Technologies to acquire Lantheus' SPECT division

New MarketBeat Followers Over Time

Media Sentiment Over Time

The Ensign Group stock logo

The Ensign Group NASDAQ:ENSG

$141.57 +4.89 (+3.58%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$141.44 -0.13 (-0.10%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The company's Skilled Services segment engages in the operation of skilled nursing facilities and rehabilitation therapy services for patients with chronic conditions, prolonged illness, and the elderly; and offers nursing facilities including specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management, as well as standard services comprising room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. Its Standard Bearer segment is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. In addition, the company provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. It operates in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$33.53 +1.27 (+3.94%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$32.61 -0.92 (-2.74%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$79.52 -2.22 (-2.72%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$80.00 +0.48 (+0.60%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.